Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

Cancer Cell
16 January 2021
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00051-9

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

LancasterOnline
14 Jan 2021
https://lancasteronline.com/news/health/halberd-corp-develops-medication-to-boost-immune-system-against-sars-cov-2-covid-19/article_78231771-5ffe-5bd0-87ec-a01a9d114ae9.html

Dr Debra Muth at the MD Custom RX LDN Book 2 Event Oct 2020 (Low dose naltrexone) from LDN Research Trust on Vimeo.

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19 (Study)

https://clinicaltrials.gov/ct2/show/NCT04604678

Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome (Study)

https://clinicaltrials.gov/ct2/show/NCT04604704

This study will assess the use of low dose naltrexone (LDN) and NAD+ for the treatment of patients with post-COVID-19 syndrome (long-COVID-19).

Naltrexone a potential therapeutic candidate for COVID-19 (Abstract)

J Biomol Struct Dyn
15 Sept 2020
https://pubmed.ncbi.nlm.nih.gov/32930058/

Survey-reported medication changes among older adults during the SARS-CoV-2 (COVID-19) pandemic (Abstract)

Res Social Adm Pharm
12 Nov 2020
https://pubmed.ncbi.nlm.nih.gov/33221267/